HTR2B
5-hydroxytryptamine receptor 2B
As of the edition of 20 October 2026, HTR2B (5-hydroxytryptamine receptor 2B, UniProt P41595) has 8 drugs tested at it and 6 companies on the list, 3 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P41595
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 15
- Disease areas
- Mental health; Pregnancy and women's health; Urinary and reproductive; Heart and blood vessels; Lungs and airways; Nervous system; Chemically induced
- Registered trials of its drugs
- 20
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Went quiet | 2 |
| Stopped | 1 |
| Withdrawn from market | 1 |
| Total | 8 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Vabicaserin | Went quiet | Phase 2 | none listed |
| Methylergonovine | Marketed | Phase 4 | none listed |
| Lisuride | Went quiet | Phase 3 | none listed |
| Mianserin | Marketed | Phase 4 | none listed |
| Prx-08066 free base | Stopped | Phase 2 | none listed |
| Clothiapine | Marketed | No phase stated | none listed |
| Methysergide | Marketed | No phase stated | none listed |
| Minaprine | Withdrawn from market | No phase stated | none listed |
8 of 8 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 1 |
| Undetermined | 2 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| Pfizer | Route A |
| Novartis | Route B |
| Axxonis Pharma | Route A |
The other 3 companies at HTR2B
In the product6 companies in all; 3 are not named here, and no score is.
See the 6 companies at HTR2B, ranked, with the facts behind eachRequest access. Nothing is shown until you do.